From Research at med.fsu.edu Mon May 6 14:19:35 2019 From: Research at med.fsu.edu (Med Research) Date: Mon, 6 May 2019 18:19:35 +0000 Subject: Weekly funding opportunities In-Reply-To: <678887EBDC79FB438BFD062B064C59A40136DE0F61@FSUCOM128.med.ad.fsu.edu> References: <60E19361B71BE04F835C1FB3C18361BE019043A56C@FSUCOM128.med.ad.fsu.edu> <678887EBDC79FB438BFD062B064C59A40136DE0F61@FSUCOM128.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE019043A74C@FSUCOM128.med.ad.fsu.edu> Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives. Due July 10, 2019; December 10, 2019; July 10, 2020; December 10, 2020; July 9, 2021; and December 10, 2021. Med-RA deadline to receive draft documents for July 2019 deadline: June 24. American Diabetes Association: Core Research Program Awards The American Diabetes Association?s Core Research Program funds research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes and its complications that hold significant promise for advancing the prevention, cure or treatment of diabetes. Basic, clinical, translational and epidemiological or health services research approaches are encouraged. Research Awards Innovative Basic Science Innovative Clinical or Translational Science Development Awards Junior Faculty Development Minority Junior Faculty Development Training Awards Postdoctoral Fellowship Minority Postdoctoral Fellowship Applications for all awards due July 15, 2019. Med-RA deadline to receive draft documents: June 27. American Association for Cancer Research: ? Johnson & Johnson Lung Cancer Innovation Science Grants The American Association for Cancer Research ? Johnson & Johnson Lung Cancer Innovation Science Grants program is a joint effort to address the need for promoting and supporting collaborative cancer research in areas that include digital therapeutics and smoking cessation, as well as biomarkers/behavioral phenotyping that bolster understanding of how lung cancer can be successfully intercepted. To that end, a grant of $1 million over three years will be awarded to a multi-institutional team in support of a new idea and/or innovative approach that has direct application and relevance to lung cancer prevention and interception. The proposed research should be translational in nature and include a clinical component with an endpoint relevant to improving the detection or treatment of lung cancer. Priority areas of interest include clinical trials that identify unique high-risk patients for lung cancer and demonstrate sustained efficacy through the measurement of both quit rates as well as disease-related biomarkers; and clinical trials that identify digital therapeutics focused on smoking avoidance for first-time smokers or for former smokers (these therapeutics may consider the impact of social engagement, gaming, and other content relevant for a population at a risk of starting or resuming the smoking habit). The inclusion of a strategic plan for clinical confirmation of the digital therapeutic study is recommended. Due July 19, 2019. Med-RA deadline to receive draft documents: July 8. NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use (SU) and substance use disorder (SUD) research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: * Courses for Skills Development: Activities may include advanced courses in a specific discipline or research area, clinical procedures for research, neuroethics in clinical research, specialized research techniques, or other topics that would complement and enhance the research experiences proposed. Additionally, career development seminars and workshops such as grant writing, manuscript preparation, and building a successful career path are encouraged. * Research Experiences: Activities include hands-on exposure to research for undergraduate students and research experiences for graduate and medical students, postdoctorates, and/or early career faculty. The nature of research experiences should be tailored to the needs and career level of participants. It is expected that mentoring will be provided in conjunction with planned research experiences. The proposed research education programs must include both courses for skills development and research experiences; however, primary emphasis should be given to research experiences. Courses for skills development should be proposed in conjunction with research experiences. Due July 22, 2019; July 22, 2020; and July 22, 2021. Med-RA deadline to receive draft documents for 2019 deadline: July 8. HLA and KIR Region Genomics in Immune-Mediated Diseases (U01 / U19 Clinical Trial Not Allowed) U01 U19 The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation. Due September 4, 2019. Med-RA deadline to receive draft documents: August 21. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon May 20 14:09:38 2019 From: Research at med.fsu.edu (Med Research) Date: Mon, 20 May 2019 18:09:38 +0000 Subject: Weekly funding opportunities In-Reply-To: <678887EBDC79FB438BFD062B064C59A40136DE6C90@FSUCOM128.med.ad.fsu.edu> References: <60E19361B71BE04F835C1FB3C18361BE019043A56C@FSUCOM128.med.ad.fsu.edu> <678887EBDC79FB438BFD062B064C59A40136DE0F61@FSUCOM128.med.ad.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE019043A74C@FSUCOM128.med.ad.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE019043B5E8@FSUCOM128.med.ad.fsu.edu> <678887EBDC79FB438BFD062B064C59A40136DE6C90@FSUCOM128.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE019043B60A@FSUCOM128.med.ad.fsu.edu> Lung Cancer Research Foundation: Pilot Grant Program The Lung Cancer Research Foundation?s annual pilot grant program provides funding for research focused on the prevention, diagnosis, treatment and cure of lung cancer. The goal of the program is to fund innovative projects across the spectrum of basic, translational, and clinical research. We encourage applications for projects investigating a wide variety of topics including: * Improving our understanding of lung cancer biology * Prevention and screening for early detection * Identification of new biomarkers and the development of targeted therapies * Development of more effective and safer therapies * Psychosocial research including supportive measures for people with lung cancer and their families * Quality of care and outcomes research for the improvement of healthcare standards and overall patient outcomes $150,000 for 2-year projects, no IDC. Due June 14, 2019. Med-RA deadline to receive draft documents: May 31. Amgen: Competitive Grant Program in Bone Research The Amgen Competitive Grant Program in Bone Research supports innovative research focused on improving the quality of osteoporosis care and patient outcomes. Specific areas of research eligible for funding through the program include longitudinal data describing long-term (5+ years) osteoporosis care relative to the diverse guidelines; effectiveness of post-fracture care programs demonstrated at a regional or global level (e.g., successfully implemented approaches and techniques, cost savings realized); delivery of optimal care for osteoporosis in the primary care setting (e.g., patient/physician dialogue, patient disease education, disease recognition); impact of osteoporosis on patient quality of life, including loss of independence; health system interventions to improve screening rates in high-risk osteoporosis patients; novel tools and approaches beyond bone-density scanning (dual X-ray absorptiometry) to identify high-risk osteoporosis patients; and solutions to improve patient adherence to their osteoporosis care regimen (e.g., ways to recognize and correct non-compliance). $150,000 for 2-year projects; full institutional indirect applied. Due June 28, 2019. Med-RA deadline to receive draft documents: June 10. Hubert and Richard Hanlon Trust: Alcohol Dependency and Abuse The Hubert and Richard Hanlon Trust funds studies and research on the causes, prevention, and cure of alcohol dependency and abuse as well as the development of effective methods of prevention, treatment, and a cure for such conditions. In support of this mission, the trust makes annual distributions of income to not-for-profit hospitals, universities, schools, foundations, and rehabilitation centers engaged in such research. $100,000 a year for 2-year projects, 10% IDC. Due (by snail mail) June 30, 2019. Med-RA deadline to receive draft documents: June 14. Damon Runyon Cancer Research Foundation Rachleff Innovation Award This award is designed to provide support for the next generation of exceptionally creative thinkers with ?high-risk/high-reward? ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. $200,000 for 2-year projects, no IDC. Stage 1 application due July 1, 2019. Med-RA deadline to receive draft documents: June 17. Harry Weaver Neuroscience Scholar Awards: National Multiple Sclerosis Society The National Multiple Sclerosis Society believes in a world free of MS and is dedicated to ensuring that people affected by MS can live their best lives. To that end, the organization is currently accepting applications for its Harry Weaver Neuroscience Scholar Award, which is named for Harry Weaver, PhD, known worldwide for his contribution to neuroscience and multiple sclerosis research. Through the program, five-year grants in support of salary and research will be awarded to highly-qualified candidates who have concluded their research training and begun their academic careers as an independent investigator in an area related to multiple sclerosis. Up to 75 percent of annual salary support may be requested, not to exceed $75,000 in year one, as well as up to $30,000 for research-associated direct costs, with incremental increases possible in each of the remaining four years. Pre-applications due August 14, 2019. Full applications due August 21, 2019. Med-RA deadline to receive draft documents: August 7. Brander Beacons Cancer Research Brander Beacons Cancer Research is accepting applications from organizations seeking funding for breakthrough research, scientists, and programs to prevent, better treat and cure breast and prostate cancer. BBCR supports academic research institutions researching tools and techniques that will increase accuracy and improve outcomes in biopsies and tumor removal procedures; identifying ways to improve patient outcomes and access; investing in emerging research and researchers; serving as an active contributor to the culture of access and innovation in cancer care. BBCR injects critical funds in increments of $5,000 to $25,000 into programs most closely connected to increased cancer prevention, better treatment outcomes, better access and, ultimately, a cure. Applications accepted on a rolling basis. Med-RA deadline to receive draft documents is ten business days before submission. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Tue May 28 11:55:28 2019 From: Research at med.fsu.edu (Med Research) Date: Tue, 28 May 2019 15:55:28 +0000 Subject: Weekly funding opportunities In-Reply-To: <60E19361B71BE04F835C1FB3C18361BE019043C486@FSUCOM128.med.ad.fsu.edu> References: <60E19361B71BE04F835C1FB3C18361BE019043A56C@FSUCOM128.med.ad.fsu.edu> <678887EBDC79FB438BFD062B064C59A40136DE0F61@FSUCOM128.med.ad.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE019043A74C@FSUCOM128.med.ad.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE019043B5E8@FSUCOM128.med.ad.fsu.edu> <678887EBDC79FB438BFD062B064C59A40136DE6C90@FSUCOM128.med.ad.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE019043B60A@FSUCOM128.med.ad.fsu.edu> <8C41A4CD-1518-4E1F-8723-E1350226A372@med.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE019043C452@FSUCOM128.med.ad.fsu.edu> <7767AA55-637F-4295-BA97-157D2C4F9F2D@med.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE019043C486@FSUCOM128.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE019043C49F@FSUCOM128.med.ad.fsu.edu> Dissemination and Implementation Research in Health (R03 / R21 R01 Clinical Trial Optional) R03 R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (?de-implement?) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Standard dates apply. Expires May 8, 2022. Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional) This funding opportunity announcement encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations. Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies. Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional) The National Cancer Institute?s (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use. R01 The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer?s disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases. Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R 21 / R01 Clinical Trial Optional) R21 R01 Through these Funding Opportunity Announcements (FOAs), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI?s priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. These FOAs include six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen. NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://urldefense.proofpoint.com/v2/url?u=https-3A__www.niaid.nih.gov_research_role&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=HISU9c_4T-Qt_gI0tcvWW97UImqSTnv9vpig387I6e8&e= ). Workshops on the Use of Adolescent Brain Cognitive Development (ABCD) Data (R25 Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA/NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. In particular, NIDA/NIMH are interested in supporting short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches. The purpose of this FOA is to invite applications that involve research education on the use of ABCD data through meetings/workshops involving 1. Advanced seminars relevant to analysis of ABCD data, and 2. Hands on collaborative- or competition-style use of the ABCD dataset. Applications emphasizing the development of predictive models for identifying group/individual differences, with the overarching goal of predicting behavioral and clinical outcomes in future timepoints, are particularly encouraged. Applications proposing prediction of outcomes within the baseline assessment (e.g., predictiing impulsivity scores at the baseline timepoint from neuroimaging measures) are encouraged to explicitly address validation strategies. The overall goals of this initiative are: * Widening use of the ABCD dataset * Enhancing rigor and reproducibility towards better predictive models * Facilitating collaboration between clinical and computational researchers on normative and psychopathological neurodevelopment. PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional) NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs. Lucidity in Dementia (R21/R33 and R21 Clinical Trial Optional) R21/R33 R21 Fluctuations in mental status occur commonly in dementia. Such fluctuations vary by dementia type and are most apparent in earlier stages of disease. However, even in late-stage dementia, patients have been reported to exhibit unexpected episodes of mental clarity or lucidity, characterized by spontaneous meaningful and relevant communication at a time when the capacity for coherent speech has presumably been lost. These FOAs are intended to advance scientific understanding of lucidity in dementia by supporting an initial set of retrospective and/or prospective studies that will lay the groundwork for further research on this topic. Results from studies supported by these FOAs have the potential to broaden our conceptual understanding of Alzheimer?s disease and related dementias. Current models of progression and functional decline do not adequately account for spontaneous reversals of cognitive ability ? even transiently ? in late-stage disease. Further study of lucid episodes in dementia could potentially expand existing paradigms and inform novel approaches for future studies. Greater understanding of lucidity in dementia may also influence families? and caregivers? attitudes and behaviors toward patients with dementia, advance understanding of personhood throughout the course of dementia, and address ethical challenges or decisional conflicts among family members or other proxies who witness lucid episodes. Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as ?cognitive systems,? that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer?s disease (AD) and Alzheimer?s disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community. Standard dates apply. Expires September 8, 2022. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri May 31 10:07:46 2019 From: Research at med.fsu.edu (Med Research) Date: Fri, 31 May 2019 14:07:46 +0000 Subject: FW: Welcome New Assistant Director of Research Accounting In-Reply-To: <0FAA3D4820668A44A11DD56DBBB6D1F7013A72BCCF@FSUCOM125.med.ad.fsu.edu> References: <3FBBF0C6CD32A441A6725F1081FEF840015B524009@FSUCOM127.med.ad.fsu.edu> <0FAA3D4820668A44A11DD56DBBB6D1F7013A72BCCF@FSUCOM125.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE019043C6AA@FSUCOM128.med.ad.fsu.edu> Please see below from Dawn Snyder. Welcome Calleen! From: Snyder, Dawn > Sent: Thursday, May 30, 2019 5:22 PM Subject: Welcome New Assistant Director of Research Accounting All - I'm happy to announce that tomorrow, Calleen Roper will be joining our COM F&A team as the new Assistant Director for Research Accounting. Calleen has been at FSU for 12 years and is intimately familiar with requirements of the Controller's Office, Procurement Services, and Sponsored Research. She has spent her entire FSU career working with all funding sources and related requirements, policies and procedures, and financial systems. Calleen's service on many committees and projects around campus has helped her develop relationships with pertinent departments, which are necessary in maintaining a strong, compliant, and well-respected post-award operations at the College of Medicine. She is well known and well respected around campus and knows the processes and people necessary to not only operate our post-award functions at FSU but improve operations. I am excited to have Calleen join our team and look forward to benefiting from her drive, creativity, experience, and exceptional customer service reputation. Thank you for helping me welcome Calleen and making her feel at home in her new F&A home. [Roper Calleen] Dawn Dawn M. Snyder, CPA Florida State University College of Medicine Senior Associate Director | Finance and Administration Chief Financial Officer | Florida Medical Practice Plan, Inc. 1115 West Call Street | Tallahassee, FL 32306-4300 V 850.645.2827 F 850.645.0577 http://med.fsu.edu/FMPP [cid:image004.png at 01D5170C.3ACAE700] PRIVILEGED AND CONFIDENTIAL: This message is intended only for the use of the Addressee(s) and may contain information that is PRIVILEGED and CONFIDENTIAL under federal or state law. If you are not the intended recipient, you are hereby notified that the use, dissemination, or copying of this information is strictly prohibited. If you received this communication in error, please erase all copies of the message and its attachments and notify the sender immediately. Please note: Florida has very broad public records laws. Most written communications to or from state/ university employees and students are public records and available to the public and media upon request. Your e-mail communications may therefore be subject to public disclosure. -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image002.jpg Type: image/jpeg Size: 4177 bytes Desc: image002.jpg URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image004.png Type: image/png Size: 17747 bytes Desc: image004.png URL: